RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Swedish Orphan Biovitrum AB (publ) - Stock

Swedish Orphan Biovitrum AB (publ) ROCE 2024

Swedish Orphan Biovitrum AB (publ) ROCE

0.14

Swedish Orphan Biovitrum AB (publ) Dividend yield

Ticker

SOBI.ST

ISIN

SE0000872095

WKN

A0LA5K

In 2024, Swedish Orphan Biovitrum AB (publ)'s return on capital employed (ROCE) was 0.14, a -18.99% increase from the 0.17 ROCE in the previous year.

Swedish Orphan Biovitrum AB (publ) Aktienanalyse

What does Swedish Orphan Biovitrum AB (publ) do?

Swedish Orphan Biovitrum AB (Sobi) is a Swedish biotechnology company specializing in rare diseases. It was founded in 1986 as Swedish Orphan International and renamed Swedish Orphan Biovitrum AB (Sobi) in 2007. Sobi is headquartered in Stockholm and is listed on NASDAQ OMX Stockholm. Its business model focuses on developing and marketing therapies for rare diseases with limited treatment options. Sobi operates in Europe, the Middle East, North Africa, and North America, collaborating closely with patient organizations and medical professionals to raise awareness of rare diseases and provide patients with access to important therapies. The company is divided into three business areas: Hemophilia, Inflammatory Diseases, and Genetic Diseases. Sobi offers medications for bleeding disorders, inflammatory diseases, and lysosomal storage diseases, among others. Some of its key products include Elocta and Alprolix for Hemophilia A and B, Kineret for autoinflammatory diseases, Synagis for respiratory syncytial virus (RSV) infections in children, Vimizim for mucopolysaccharidosis type IVA, and Orfadin for hereditary tyrosinemia type 1. In conclusion, Sobi is a leading biotechnology company dedicated to developing and marketing therapies for rare diseases, with a wide range of products in its portfolio. It collaborates with patient organizations and strives to improve the quality of life for patients with rare diseases. Swedish Orphan Biovitrum AB (publ) ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling Swedish Orphan Biovitrum AB (publ)'s Return on Capital Employed (ROCE)

Swedish Orphan Biovitrum AB (publ)'s Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Swedish Orphan Biovitrum AB (publ)'s ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Swedish Orphan Biovitrum AB (publ)'s ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Swedish Orphan Biovitrum AB (publ)’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Swedish Orphan Biovitrum AB (publ) Stock

What is the ROCE (Return on Capital Employed) of Swedish Orphan Biovitrum AB (publ) this year?

The ROCE of Swedish Orphan Biovitrum AB (publ) is 0.14 undefined this year.

How has the ROCE (Return on Capital Employed) of Swedish Orphan Biovitrum AB (publ) developed compared to the previous year?

The ROCE of Swedish Orphan Biovitrum AB (publ) has increased by -18.99% decreased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of Swedish Orphan Biovitrum AB (publ)?

A high Return on Capital Employed (ROCE) indicates that Swedish Orphan Biovitrum AB (publ) has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of Swedish Orphan Biovitrum AB (publ)?

A low ROCE (Return on Capital Employed) can indicate that Swedish Orphan Biovitrum AB (publ) has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from Swedish Orphan Biovitrum AB (publ) impact the company?

An increase in the ROCE of Swedish Orphan Biovitrum AB (publ) can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of Swedish Orphan Biovitrum AB (publ) affect the company?

A decrease in ROCE of Swedish Orphan Biovitrum AB (publ) can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of Swedish Orphan Biovitrum AB (publ)?

Some factors that can affect Swedish Orphan Biovitrum AB (publ)'s ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of Swedish Orphan Biovitrum AB (publ) so important for investors?

The ROCE of Swedish Orphan Biovitrum AB (publ) is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can Swedish Orphan Biovitrum AB (publ) take to improve the ROCE?

To improve the ROCE, Swedish Orphan Biovitrum AB (publ) can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does Swedish Orphan Biovitrum AB (publ) pay?

Over the past 12 months, Swedish Orphan Biovitrum AB (publ) paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Swedish Orphan Biovitrum AB (publ) is expected to pay a dividend of 0 SEK.

What is the dividend yield of Swedish Orphan Biovitrum AB (publ)?

The current dividend yield of Swedish Orphan Biovitrum AB (publ) is .

When does Swedish Orphan Biovitrum AB (publ) pay dividends?

Swedish Orphan Biovitrum AB (publ) pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Swedish Orphan Biovitrum AB (publ)?

Swedish Orphan Biovitrum AB (publ) paid dividends every year for the past 0 years.

What is the dividend of Swedish Orphan Biovitrum AB (publ)?

For the upcoming 12 months, dividends amounting to 0 SEK are expected. This corresponds to a dividend yield of 0 %.

In which sector is Swedish Orphan Biovitrum AB (publ) located?

Swedish Orphan Biovitrum AB (publ) is assigned to the 'Health' sector.

Wann musste ich die Aktien von Swedish Orphan Biovitrum AB (publ) kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Swedish Orphan Biovitrum AB (publ) from 6/7/2024 amounting to 0 SEK, you needed to have the stock in your portfolio before the ex-date on 6/7/2024.

When did Swedish Orphan Biovitrum AB (publ) pay the last dividend?

The last dividend was paid out on 6/7/2024.

What was the dividend of Swedish Orphan Biovitrum AB (publ) in the year 2023?

In the year 2023, Swedish Orphan Biovitrum AB (publ) distributed 0 SEK as dividends.

In which currency does Swedish Orphan Biovitrum AB (publ) pay out the dividend?

The dividends of Swedish Orphan Biovitrum AB (publ) are distributed in SEK.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Swedish Orphan Biovitrum AB (publ)

Our stock analysis for Swedish Orphan Biovitrum AB (publ) Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Swedish Orphan Biovitrum AB (publ) Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.